PERSON
Coherus BioSciences Completes Strategic Shift with $483M Sale of Last Biosimilar Asset
Coherus BioSciences, biosimilars, strategic pivot, pharmaceutical industry, biotechnology
Coherus BioSciences Sells Udenyca Franchise to Intas Pharmaceuticals for $558.4 Million
Coherus BioSciences, Udenyca, Intas Pharmaceuticals, pegfilgrastim-cbqv, immuno-oncology, pharmaceutical deal
Ipsen and Biomunex Partner on First-in-Class MAIT Cell Engager for Solid Tumors in $610M Deal
Ipsen, Biomunex, MAIT cell engager, T cell engager, solid tumors, immuno-oncology, BMX-502, BiXAb technology, GPC3 tumor antigen.
Olema Secures $250 Million Funding for Pivotal Breast Cancer Trial Featuring Novartis’ Kisqali
Olema, Breast Cancer, Novartis, Kisqali, Pivotal Trial, Funding
Kronos Undergoes Major Restructuring: CEO Norbert Bischofberger Exits Amid 83% Workforce Reduction
Kronos layoffs, Norbert Bischofberger, biotech industry, workforce reduction, restructuring
Outlook Therapeutics to Resubmit BLA for ONS-5010 Despite Missing Primary Endpoint in NORSE EIGHT Trial
Outlook Therapeutics, ONS-5010, Lytenava, Wet Age-Related Macular Degeneration (wet AMD), Biologics License Application (BLA), NORSE EIGHT Trial, FDA Approval
Embecta Discontinues Insulin Patch Pump Program Amid Restructuring Efforts
Embecta, insulin patch pump, discontinuation, restructuring, layoffs, diabetes technology
CDC Faces Uncertainty Amid Leadership Change and Funding Threats
CDC, leadership change, funding threats, public health, emerging health threats, Dave Weldon, Dr. Mandy Cohen
FDA Approves BridgeBio’s Attruby for ATTR-CM, Offering New Hope for Patients
Attruby, BridgeBio, ATTR-CM, FDA approval, transthyretin amyloid cardiomyopathy, acoramidis, TTR stabilizer
Adragos Pharma Expands Global Reach with Acquisition of Swiss CDMO Baccinex
Adragos Pharma, Baccinex, CDMO, aseptic fill-finish, sterile drug production, pharmaceutical manufacturing